Eli Lilly stock moved back toward record territory after the drugmaker delivered a powerful first-quarter 2026 earnings report, raised full-year revenue guidance, and showed that its growth engine extends beyond blockbuster obesity medicines. Shares traded around $1,010.95, up 2.26% in the latest session, leaving the company with a market value of roughly $959.32 billion.
The headline figures were difficult for the market to ignore. First-quarter revenue rose 55.54% year over year to $19.80 billion, while diluted earnings per share reached $8.55, well above expectations. Net income increased 168.07% to $7.40 billion, underscoring how quickly scale in Lilly’s product portfolio is translating into profitability.
The next phase of the story now centers on durability. Mounjaro and Zepbound remain the core growth drivers, but early traction for oral obesity drug Foundayo, pipeline progress from retatrutide, and strong gains from EBGLYSS and JAYPIRCA suggest Lilly is building a broader platform rather than relying on a single franchise.
Key Facts
- Eli Lilly reported Q1 2026 revenue of $19.80 billion, up 55.54% from a year earlier.
- Diluted EPS reached $8.55 in the quarter, compared with consensus expectations near $6.79.
- Net income surged 168.07% to $7.40 billion, while EBITDA rose 78.44% to $10.29 billion.
- Mounjaro generated $8.66 billion in quarterly revenue and Zepbound added $4.16 billion, for a combined $12.82 billion.
- The company lifted 2026 revenue guidance by $2 billion to a range of $82 billion to $85 billion.
Eli Lilly Stock
The latest move in Eli Lilly stock reflects more than a strong quarter. It signals continued investor confidence that Lilly is converting its leadership in obesity and diabetes into a multi-year earnings cycle. With a trailing P/E near 35.92 and a forward P/E around 27.30, the shares still trade at a premium to many large pharmaceutical peers, but that valuation is being supported by unusually fast revenue and profit growth.
Mounjaro and Zepbound remain central to the investment case. The two tirzepatide-based products delivered $12.82 billion in combined quarterly revenue, a level that exceeds the annual sales of many major drugmakers. Their commercial strength matters because obesity and diabetes are among the largest therapeutic markets in healthcare, and Lilly has built both clinical and manufacturing advantages that are difficult for competitors to match quickly.
What broadens the story is the company’s newer pipeline and adjacent businesses. Foundayo, the oral obesity and diabetes therapy also known as orforglipron, logged 7,335 U.S. prescriptions in its first four weeks after April 1 approval. Meanwhile, immunology drug EBGLYSS posted 141% sales growth to $145 million, and oncology treatment JAYPIRCA rose 79% to $165 million. For investors, that combination reduces the risk that Lilly’s growth narrative depends on only one category.
Eli Lilly is no longer being valued only as an obesity leader; it is being valued as a pharmaceutical company with technology-style growth and a pipeline deep enough to defend it.
Why the pipeline is becoming the key valuation debate
One of the most closely watched assets is retatrutide, Lilly’s triple-agonist candidate targeting GLP-1, GIP, and glucagon receptors. In the TRIUMPH-4 trial in obesity plus knee osteoarthritis, the therapy delivered mean weight loss of about 29% over 68 weeks. That result stands out because it moves beyond incremental improvement and begins to challenge the efficacy traditionally associated with bariatric surgery.
If later-stage data and regulators support that profile, retatrutide could open a particularly important segment of the obesity market: patients with severe obesity who need more substantial weight reduction than current therapies typically provide. Lilly plans regulatory submissions in obesity, sleep apnea, and osteoarthritis of the knee during 2026, creating a catalyst calendar that could keep the stock in focus.
Implications for Investors
For portfolio managers, Eli Lilly presents a familiar trade-off: exceptional growth at an expensive headline multiple. The bullish argument is that earnings are expanding fast enough to make the valuation look less stretched over time. Revenue growth of 47.43% on a trailing 12-month basis, expanding margins, and a guidance increase all support that case. Free cash flow also improved sharply, reaching $2.11 billion after a negative comparable period a year earlier.
The opportunity lies in Lilly’s ability to remain the leading listed vehicle for exposure to the obesity treatment market. In addition to injectable products, the launch of Foundayo gives the company a second route into a massive addressable population, including international markets where pills may be more scalable and affordable than injectables. Manufacturing advantages in both peptide and small-molecule production could become as important as clinical efficacy in determining market share over the next several years.
The main risks are also clear. Competition is intensifying across obesity, with large rivals developing next-generation injectable and oral therapies. Pipeline execution remains critical, particularly for retatrutide, where safety scrutiny could shape the ultimate commercial opportunity. Investors should also monitor how Lilly manages post-2030 patent exposure across several franchises, even as it uses current cash generation to invest in new growth platforms.
With shares still below the 52-week high of $1,133.95 but far above the 52-week low of $623.78, the market is signaling confidence without assuming a flawless path. The next major test for Eli Lilly stock will be whether prescription growth, new indications, and supply execution continue to justify premium expectations through the rest of 2026.
VIP Trading Signals
